Comparative studies on the clinical features and outcomes of triple-negative subgroups to human epidermal growth factor receptor-2 (HER-2) overexpression, and luminal A and B subgroups in lymph node-negative breast cancer patients, are important to correctly evaluate clinical prognosis. A total of 1132 Chinese breast cancer patients were enrolled in a retrospective analysis. We characterized an...

Triple-negative breast cancer represents approximately 15%-20% of all newly diagnosed breast cancers, but it accounts for a disproportionate number of breast cancer-related deaths each year. Owing to the lack of estrogen, progesterone, and human epidermal growth factor receptor 2 expression, patients with triple-negative breast cancer do not benefit from generally well-tolerated and effective t...

background: for xenograft models of triple-negative breast cancer (tnbc) to be valuable in development of molecularly-targeted drugs, careful characterization is essential to their validation. the present study aimed to validate the tnbc xenograft model with a specific focus on angiogenesis. methods : twelve tnbc xenograft tumors and 12 human breast cancer tumors (htnbc) were included in this s...

BACKGROUND The possible role of viruses in breast cancer etiology remains an unresolved question. We hypothesized that if some viruses are involved, it may be in a subgroup of breast cancers only. Epidemiological arguments drove our interest in breast cancer subgroups that are more frequent in Africa, namely inflammatory breast cancer (IBC) and triple-negative breast cancer. We tested whether v...

IMPAKT is an international conference dedicated to translational research and drug development in breast cancer. IMPAKT focused this year on PI3K and metabolism, next generation sequencing and tumor heterogeneity, triple negative breast cancers and implementation of gene expression arrays in daily practice. Several key messages were delivered during the conference. Firstly, PI3K has very strong...